Vitrolife AB Stock price

Equities

VITR

SE0011205202

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe Europe 05:28:57 2024-02-23 am EST 5-day change 1st Jan Change
181.6 SEK -2.60% Intraday chart for Vitrolife AB -4.81% -6.52%
Sales 2023 3.51B 341M Sales 2024 * 3.79B 367M Capitalization 25.25B 2.45B
Net income 2023 -3.85B -374M Net income 2024 * 602M 58.41M EV / Sales 2023 7.86 x
Net Debt 2023 1.23B 119M Net Debt 2024 * 613M 59.5M EV / Sales 2024 * 6.83 x
P/E ratio 2023
-6.85 x
P/E ratio 2024 *
43 x
Employees 1,123
Yield 2023
0.51%
Yield 2024 *
0.62%
Free-Float 55.39%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.91%
1 week-3.32%
Current month+8.18%
1 month+10.95%
3 months+2.47%
6 months+19.94%
Current year-4.21%
More quotes
1 week
185.30
Extreme 185.3
194.90
1 month
165.70
Extreme 165.7
198.90
Current year
162.90
Extreme 162.9
198.90
1 year
123.90
Extreme 123.9
244.20
3 years
123.90
Extreme 123.9
585.00
5 years
112.30
Extreme 112.3
585.00
10 years
18.00
Extreme 18
585.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-07-31
Director of Finance/CFO 54 21-12-31
Chairman 68 15-05-06
Members of the board TitleAgeSince
Director/Board Member 53 19-05-01
Chairman 68 15-05-06
Director/Board Member 64 18-04-26
More insiders
Date Price Change Volume
24-02-23 182 -2.41% 86 184
24-02-22 186.5 -1.06% 83,559
24-02-21 188.5 -0.21% 39,815
24-02-20 188.9 +0.48% 33,069
24-02-19 188 -1.67% 29,600

Delayed Quote Nasdaq Stockholm, February 22, 2024 at 11:29 am EST

More quotes
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company's product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
186.5 SEK
Average target price
248.3 SEK
Spread / Average Target
+33.15%
Consensus
  1. Stock
  2. Equities
  3. Stock Vitrolife AB - Nasdaq Stockholm
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer